Synovial Sarcoma - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Synovial Sarcoma - Pipeline Review, H2 2015’, provides an overview of the Synovial Sarcoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Synovial Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Synovial Sarcoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Synovial Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Synovial Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Synovial Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Synovial Sarcoma Overview
- Therapeutics Development
- Pipeline Products for Synovial Sarcoma - Overview
- Pipeline Products for Synovial Sarcoma - Comparative Analysis
- Synovial Sarcoma - Therapeutics under Development by Companies
- Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes
- Synovial Sarcoma - Pipeline Products Glance
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Synovial Sarcoma - Products under Development by Companies
- Synovial Sarcoma - Products under Investigation by Universities/Institutes
- Synovial Sarcoma - Companies Involved in Therapeutics Development
- Adaptimmune Limited
- EpiZyme, Inc.
- Immune Design Corp.
- Karyopharm Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- OncoTherapy Science, Inc.
- Synovial Sarcoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (ID-LV305 + ID-G305) - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- everolimus - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- OTSA-101 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- pembrolizumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- selinexor - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SSTC-104 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- tazemetostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Synovial Sarcoma - Recent Pipeline Updates
- Synovial Sarcoma - Discontinued Products
- Synovial Sarcoma - Product Development Milestones
- Featured News & Press Releases
- Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US
- Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Synovial Sarcoma, H2 2015
- Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Number of Products under Investigation by Universities/Institutes, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Comparative Analysis by Early Stage Development, H2 2015
- Comparative Analysis by Unknown Stage Development, H2 2015
- Products under Development by Companies, H2 2015
- Products under Investigation by Universities/Institutes, H2 2015
- Synovial Sarcoma - Pipeline by Adaptimmune Limited, H2 2015
- Synovial Sarcoma - Pipeline by EpiZyme, Inc., H2 2015
- Synovial Sarcoma - Pipeline by Immune Design Corp., H2 2015
- Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
- Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2015
- Synovial Sarcoma - Pipeline by Novartis AG, H2 2015
- Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2015
- Assessment by Monotherapy Products, H2 2015
- Assessment by Combination Products, H2 2015
- Number of Products by Stage and Target, H2 2015
- Number of Products by Stage and Mechanism of Action, H2 2015
- Number of Products by Stage and Route of Administration, H2 2015
- Number of Products by Stage and Molecule Type, H2 2015
- Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015
- Synovial Sarcoma - Discontinued Products, H2 2015
- List of Figures
- Number of Products under Development for Synovial Sarcoma, H2 2015
- Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2015
- Number of Products under Development by Companies, H2 2015
- Comparative Analysis by Clinical Stage Development, H2 2015
- Assessment by Monotherapy Products, H2 2015
- Number of Products by Top 10 Targets, H2 2015
- Number of Products by Stage and Top 10 Targets, H2 2015
- Number of Products by Top 10 Mechanism of Actions, H2 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
- Number of Products by Top 10 Routes of Administration, H2 2015
- Number of Products by Stage and Top 10 Routes of Administration, H2 2015
- Number of Products by Top 10 Molecule Types, H2 2015
- Number of Products by Stage and Top 10 Molecule Types, H2 2015
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook